IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, has partnered with Grifols, a global healthcare company and producer of plasma-derived medicines and innovative diagnostic solutions, to transform the specialty diagnostics market.

Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols’ random access, single molecule counting (SMC) platform. These panels will address key customer needs in specialty diagnostics, offering solutions for laboratories and patients alike. The agreement includes a framework for product development, manufacturing and commercialization, ensuring a reliable and efficient delivery to the market.

The project brings together IBL’s expertise in specialty diagnostic assay development and Grifols’ leadership in diagnostic instrumentation. The collaboration encompasses:

• Development of biomarker panels by IBL, tailored for random access on the SMC Platform.
• Manufacturing and supply of these products by IBL under a master supply agreement.

“Partnering with Grifols allows us to scale healthcare innovation globally,” said Mukta Acharya, Head of Tecan’s Life Sciences Business. “By leveraging IBL’s entrepreneurial spirit and technological expertise, we’re addressing unmet needs in specialty diagnostics. Together, we’re creating solutions that empower laboratories and enhance patient journeys with reliable and sensitive diagnostics.”

“Our collaboration with IBL demonstrates our commitment to our strategic plan for developing innovative clinical diagnostic solutions,” added Guillermo Marco-Gardoqui, SVP Diagnostic Operations and Strategy at Grifols. “By integrating IBL’s biomarker panels with the advanced capabilities of the SMC Platform, we are enhancing clinical workflows and addressing critical gaps in patient care.”